NICE recommends reduced-impact Mepact from Takeda for bone cancer
This article was originally published in Scrip
Executive Summary
In a U-turn, NICE, the health technology institute for England and Wales, has recommended Takeda's bone cancer drug, Mepact (mifamurtide), but only when it's made available at a reduced cost to the NHS under a patient access scheme.